SEARCH

SEARCH BY CITATION

Thumbnail image of

Pediatric Allergy and Immunology (PAI) is joined in celebrating its 25th year by a scientific community of pediatric allergists/immunologists that has become global over the years. With this issue our journal can look back on a quarter of a century filled with remarkable development: 25 yr ago a few pioneers gathered as a working group, which was the basis of the European Society for Paediatric Allergy and Immunology (ESPACI). A few enthusiastic researchers from the United States, Japan, Australia, and other Asia–Pacific countries joined in to form a new platform, which was intended to facilitate communication about innovative research in our area of interest, to induce lively discussions, allow critical evaluation of controversial issues, and to announce the progress made in diagnosis and treatment of allergic and immune-mediated diseases, as well as provide novel ideas for the prevention and early intervention of allergies including asthma [1-15].

At that time, allergology all over the world was considered to be a relatively new and consequently still weak discipline of clinical science. Therefore, not everyone shared the enthusiasm of pediatricians who thought that there were specific issues to address which would justify a subspecialty of allergology for pediatricians and a journal with a strong pediatric profile. The two editors in chief, Professor Bengt Björkstén from Linköping, Sweden and later Professor John Warner from London, UK, provided the basis of a successful development together with many key scientists from all over the world. Their professional expertise as well as their strong commitment turned out to be crucial for the remarkable success of the journal over the decades.

Today it seems appropriate for me to ask some of the outstanding researchers, including the two past chief editors of our journal, to update the state of the art, express their opinions about our specialty and its current standing as well as give some advice for novel directions of research for the future [17-25].

It appears that the scientific impact—the visibility as well as the global distribution of our journal—has developed in a really remarkable way, and many clinicians and scientists who have contributed a lot of effort and time over the years as reviewers, members of the editorial group or professionals working in the editorial office deserve credit for it. A special thanks goes to the Paediatric Section of the European Academy of Allergy and Clinical Immunology (EAACI) as well as the junior members of our academy who became strong partners and supporters of our journal [16].

The aims for the next 25 yr are quite obvious:

  1. Our journal has continuously to demonstrate that pediatric allergists all over the world have specific tasks in patient care as well as a specific and unique research agenda. Reflecting the atopic march with all its genetic, environmental, and lifestyle determinants to find reasonable windows of opportunities for prevention will remain a key task for the future.
  2. Children with allergic and immunoallergic diseases, including asthma, have the same right to evidence-based diagnosis, treatment, and prevention as is commonly requested for adults. It is an important step forward that authorities such as the European Medicines Agency (EMA) are considering a pediatric investigational plan mandatory for any new registered drug including products for immunotherapy.

For me, it is a great privilege to serve together with my editorial team in Berlin to make our journal even stronger in the future as the common platform of communication between clinicians and researchers, ensuring the very best for our patients.

Key issues in the development of pediatric allergology as a specialty
Description of the natural history of allergic manifestations and improved understanding of its determinants
Evaluation of the use for diagnostic tests in the early periods of the atopic march
Assessment of the efficacy and safety of dietary, environmental, pharmacotherapeutic, and immunotherapeutic approaches in infancy and childhood
Provision of evidence for interventions aiming at primary and secondary prevention

References

  1. Top of page
  2. References